We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can Alnylam's Broader Portfolio Ease Its Dependence on Amvuttra?
Read MoreHide Full Article
Key Takeaways
Amvuttra drives Alnylam's top line through expanded label and as patients switch from Onpattro.
Givlaari, Oxlumo, and royalties from Leqvio add incremental revenues and global growth potential.
Rare disease drugs delivered $236.8M in H1 2025 revenues, up 16% year over year.
Alnylam Pharmaceuticals’ (ALNY - Free Report) primary top-line driver is its newest drug, Amvuttra (vutrisiran), which is approved in the United States and the EU for treating the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis and ATTR amyloidosis with cardiomyopathy (ATTR-CM). The drug’s phenomenal uptake has been driven by new patients starting treatment as well as several patients switching from Onpattro (patisiran), ALNY’s first FDA-approved drug for hATTR amyloidosis.
Alnylam also markets several other products across rare disease and cardiovascular markets, providing the company with incremental revenues that add to the top line.
Givlaari (givosiran) is approved in both the United States and the EU for treating adults with acute hepatic porphyria, with the EU also approving the drug for use in adolescents. Strong uptake has made Givlaari a meaningful revenue driver, and Alnylam is actively working on regulatory submissions in additional regions through 2025 and beyond to widen its global presence.
Similarly, Oxlumo (lumasiran) injection was initially approved in the United States and the EU for the treatment of primary hyperoxaluria type 1, to lower urinary oxalate levels in pediatric and adult patients. Later, the drug’s label was expanded to include lowering urinary and plasma oxalate levels. This expansion, coupled with pending regulatory filings in additional territories, strengthens its potential for international growth.
Alnylam also markets a fifth drug, Leqvio (inclisiran), in collaboration with Novartis (NVS - Free Report) to treat hypercholesterolemia in the EU. In the United States, it is approved to reduce low-density lipoprotein cholesterol. The drug’s label has also been expanded to cover high-risk cardiovascular patients and late-stage studies are underway to broaden its indication further. ALNY earns royalties from Novartis for Leqvio sales that add to the top line.
In the first half of 2025, Alnylam generated $236.8 million in net product revenues from its rare disease portfolio (Givlaari and Oxlumo), reflecting a 16% year-over-year increase. Expanding global adoption of these therapies is expected to sustain Alnylam’s top-line growth while diversifying its revenue streams and reducing reliance on Amvuttra.
ALNY’s Competition in the Market for Its Lead Drug
Alnylam’s push to broaden indications and expand the global reach of its marketed drugs is becoming increasingly critical as Amvuttra faces intensifying competition in the ATTR-CM market. Rival therapies, including Pfizer’s (PFE - Free Report) Vyndaqel/Vyndamax (tafamidis) and BridgeBio’s (BBIO - Free Report) Attruby (acoramidis), are already approved and competing for market share in this space.
Vyndaqel is one of the key in-line products that has driven improvement in Pfizer’s revenues in the first half of 2025. Global Vyndaqel family revenues of $3.1 billion rose 27% year over year in the first half of 2025, driven by continued demand growth due to increases in diagnosis and treatment rates, primarily in the United States and developed Europe. Pfizer’s Vyndaqel family includes global revenues from Vyndaqel as well as revenues for Vyndamax in the United States and Vynmac in Japan.
Approved in late 2024, Attruby is BridgeBio’s only marketed product. The drug generated sales worth $108.2 million in the first half of 2025, driven by solid uptake. BBIO reported that as of Aug. 1, 2025, 3,751 unique patient prescriptions for Attruby have been written by 1,074 unique healthcare providers since approval. BridgeBio is also currently evaluating acoramidis for the prevention of early-stage variant transthyretin amyloidosis in a late-stage study.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Can Alnylam's Broader Portfolio Ease Its Dependence on Amvuttra?
Key Takeaways
Alnylam Pharmaceuticals’ (ALNY - Free Report) primary top-line driver is its newest drug, Amvuttra (vutrisiran), which is approved in the United States and the EU for treating the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis and ATTR amyloidosis with cardiomyopathy (ATTR-CM). The drug’s phenomenal uptake has been driven by new patients starting treatment as well as several patients switching from Onpattro (patisiran), ALNY’s first FDA-approved drug for hATTR amyloidosis.
Alnylam also markets several other products across rare disease and cardiovascular markets, providing the company with incremental revenues that add to the top line.
Givlaari (givosiran) is approved in both the United States and the EU for treating adults with acute hepatic porphyria, with the EU also approving the drug for use in adolescents. Strong uptake has made Givlaari a meaningful revenue driver, and Alnylam is actively working on regulatory submissions in additional regions through 2025 and beyond to widen its global presence.
Similarly, Oxlumo (lumasiran) injection was initially approved in the United States and the EU for the treatment of primary hyperoxaluria type 1, to lower urinary oxalate levels in pediatric and adult patients. Later, the drug’s label was expanded to include lowering urinary and plasma oxalate levels. This expansion, coupled with pending regulatory filings in additional territories, strengthens its potential for international growth.
Alnylam also markets a fifth drug, Leqvio (inclisiran), in collaboration with Novartis (NVS - Free Report) to treat hypercholesterolemia in the EU. In the United States, it is approved to reduce low-density lipoprotein cholesterol. The drug’s label has also been expanded to cover high-risk cardiovascular patients and late-stage studies are underway to broaden its indication further. ALNY earns royalties from Novartis for Leqvio sales that add to the top line.
In the first half of 2025, Alnylam generated $236.8 million in net product revenues from its rare disease portfolio (Givlaari and Oxlumo), reflecting a 16% year-over-year increase. Expanding global adoption of these therapies is expected to sustain Alnylam’s top-line growth while diversifying its revenue streams and reducing reliance on Amvuttra.
ALNY’s Competition in the Market for Its Lead Drug
Alnylam’s push to broaden indications and expand the global reach of its marketed drugs is becoming increasingly critical as Amvuttra faces intensifying competition in the ATTR-CM market. Rival therapies, including Pfizer’s (PFE - Free Report) Vyndaqel/Vyndamax (tafamidis) and BridgeBio’s (BBIO - Free Report) Attruby (acoramidis), are already approved and competing for market share in this space.
Vyndaqel is one of the key in-line products that has driven improvement in Pfizer’s revenues in the first half of 2025. Global Vyndaqel family revenues of $3.1 billion rose 27% year over year in the first half of 2025, driven by continued demand growth due to increases in diagnosis and treatment rates, primarily in the United States and developed Europe. Pfizer’s Vyndaqel family includes global revenues from Vyndaqel as well as revenues for Vyndamax in the United States and Vynmac in Japan.
Approved in late 2024, Attruby is BridgeBio’s only marketed product. The drug generated sales worth $108.2 million in the first half of 2025, driven by solid uptake. BBIO reported that as of Aug. 1, 2025, 3,751 unique patient prescriptions for Attruby have been written by 1,074 unique healthcare providers since approval. BridgeBio is also currently evaluating acoramidis for the prevention of early-stage variant transthyretin amyloidosis in a late-stage study.